Sacubitrilo / Valsartán: a jump of quality in the treatment of the heart inadequacy

Montes de Oca Zubizarreta, Victorero, Aguilar Cuba and Careaga Valido

Health Leadership and Quality of Life, 2024, vol. 3, .668

Abstract: Introduction: The advances in the prevention, diagnosis and treatment of the cardiovascular illnesses have been excellent, taking place significant reductions of the rates of mortality; it has not happened this way with the heart inadequacy; the high indexes of hospitalization, disability, morbilidad, mortality that takes place, took to the necessity of developing new fármacos, fruit of this the obtaining of Sacubitrilo/Valsartán, medication that inhibits system renina-angiotensina-aldosterona, was and it retards the degradation of the péptidos natriuréticos. The results of several studies took to that from the year 2021 were included in the basic pillars for the treatment of the inadequacy. Method: He/she was carried out a search in several bibliographical databases, revising the clinical studies published on the use of the medication. Results: The PARADIGM-HF was the first rehearsal that showed its benefits, with significant reduction of the mortality and the hospitalizations; other publications have confirmed their effectiveness, security, tolerance and improvement of the functional and renal capacity. Conclusions: The weight of the accumulated evidence, with the use of Sacubitrilo/Valsartán is incontrastable and its introduction in the clinical practice, he/she will go consolidating its indication in the treatment protocols that a revolutionary change will imply in the presage and with it the so yearned reduction of the mortality and the hospital entrance.

Date: 2024
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:health:v:3:y:2024:i::p:.668:id:.668

DOI: 10.56294/hl2024.668

Access Statistics for this article

More articles in Health Leadership and Quality of Life from AG Editor
Bibliographic data for series maintained by Javier Gonzalez-Argote ().